KRAS and cancer: Among all combination strategies to enhance the antitumor activity of KRAS G12C inhibitors (9–12, 56), the inhibition of SHP2, which connects RTKs to the RAS signaling pathway and is particularly vulnerable in cancer cells with genetic alteration in KRAS, has attracted considerable attention (12, 56–59).